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Objectives: To identify patterns (clusters) of damage manifestation within a large cohort of juvenile SLE (jSLE)
patients and evaluate their possible association with mortality.
Methods: This is a multicentre, descriptive, cross-sectional study of a cohort of 345 jSLE patients from the
Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus
International Collaborating Clinics Damage Index. Using cluster analysis, groups of patients with similar pat-
terns of damage manifestation were identified and compared.
Results: Mean age (years)§ S.D. at diagnosis was 14.2§ 2.89; 88.7% were female and 93.4% were Caucasian.
Mean SLICC/ACR DI§ S.D. was 1.27§ 1.63. A total of 12 (3.5%) patients died. Three damage clusters were
identified: Cluster 1 (72.7% of patients) presented a lower number of individuals with damage (22.3% vs.
100% in Clusters 2 and 3, P< 0.001); Cluster 2 (14.5% of patients) was characterized by renal damage in 60%
of patients, significantly more than Clusters 1 and 3 (P< 0.001), in addition to increased more ocular, cardio-
vascular and gonadal damage; Cluster 3 (12.7%) was the only group with musculoskeletal damage (100%),
significantly higher than in Clusters 1 and 2 (P< 0.001). The overall mortality rate in Cluster 2 was 2.2 times
higher than that in Cluster 3 and 5 times higher than that in Cluster 1 (P< 0.017 for both comparisons).
Conclusions: In a large cohort of jSLE patients, renal and musculoskeletal damage manifestations were the
two dominant forms of damage by which patients were sorted into clinically meaningful clusters. We found
two clusters of jSLE with important clinical damage that were associated with higher rates of mortality, espe-
cially for the cluster of patients with predominant renal damage. Physicians should be particularly vigilant to
the early prevention of damage in this subset of jSLE patients with kidney involvement.
© 2018 Elsevier Inc. All rights reserved.Keywords:
Juvenile Systemic Lupus Erythematosus
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Cluster analysis
RELESSERIntroduction
Systemic lupus erythematosus (SLE) is a complex systemic rheu-
matic disease in which several domains should be assessed: disease
activity, organ damage and health-related quality of life [1]. As sur-
vival in SLE patients has improved over the past decades [2,3], evalua-
tion of organ damage has become more relevant.
Damage in SLE is defined as an irreversible change, unrelated to
active inflammation, that occurs after diagnosis of the disease, and
which is present for at least 6 months [4]. The Systemic Lupus Inter-
national Collaborating Clinics (SLICC)/American College of Rheuma-
tology (ACR) Damage Index (SDI) has been shown to be a valid and
reliable measure for damage in SLE [46].
Several studies have shown that organ damage predicts future
mortality in SLE patients, usually by using the global SDI score to ana-
lyze the association between damage and mortality [715]. Very
few studies have assessed damage clustering and the impact of the
different SDI domains on survival [1618]. Recently, our RELESSER
Study Group has detected three clusters associated with different
mortality rates in our entire SLE cohort, mainly based on the propor-
tion of patients with musculoskeletal and cardiovascular damage
[18]. Our group also compared juvenile-onset SLE (jSLE) and adult-
onset SLE (aSLE) patients within RELESSER without finding significant
differences in the mortality rate between the two subgroups [19].
However, cluster analysis of damage manifestations and their poten-
tial association with mortality in jSLE patients has not been carried
out.
Therefore, the primary objective of our study was to identify pat-
terns (clusters) of damage manifestation within a large cohort of jSLE
patients. In addition, we sought to evaluate the potential association
of these clusters with the risk of mortality in jSLE.
Patients and methods
Research study network
The Registry of Systemic Lupus Erythematosus Patients of the
Spanish Society of Rheumatology (RELESSER) is a hospital-based reg-
istry that consists of two stages. The first one is a cross-sectional stage
whose main objective is to describe the characteristics and comorbid-
ities of the patients diagnosed with SLE in Spain. This is followed by alongitudinal follow-up stage over time with repeated yearly visits.
The RELESSER Registry was conducted by the Systemic Autoimmune
Diseases Study Group of the Spanish Society of Rheumatology and
involved 45 rheumatology departments. All investigators signed a
written commitment before participating. Informed consent was
obtained from all patients who participated in the longitudinal stage.
The study was approved by the local ethics committees of the partici-
pating centres in accordance with the Declaration of Helsinki’s guide-
lines for research in humans.
Study design
This is a national, multicentre, descriptive study of a cohort with a
cross-sectional analysis, conducted at the time of the last medical visit,
of every patient (or death, if applicable). A detailed description of its
methodology has been previously published [18]. Briefly, a specific pro-
tocol was created to collect »400 variables per patient. Information was
obtained by reviewing clinical histories and electronically compiled.
Before starting the data collection, in order to minimize missing data, all
investigators were encouraged to carry out a census of their SLE patients
and complete any missing data. In order to ensure data homogeneity
and quality, every item in the protocol had a highly standardized defini-
tion. A training course for investigators was first carried out to avoid
information bias and all investigators had online access to guidelines on
how to complete the protocol. The first patient was entered in October
2011. Electronic data collection finished in August 2012. Subsequently, a
professional monitor with experience in rheumatologic studies
reviewed the database and detected missing or inconsistent data, which
were discussed with the principal investigators and sent to the sub-
investigators for additions and corrections.
Patients
The RELESSER database includes unselected consecutive SLE
patients. For the purpose of the present study, we selected all patients
who fulfilled the following inclusion criteria: (a) age at SLE diagnosis
< 18 years and (b)  4 American College of Rheumatology (ACR) 1997
criteria for the classification of SLE [19,20]. There were no specific
exclusion criteria.
In order to avoid selection bias, patients were widely and homo-
geneously spread across Spain. Virtually all patients with SLE treated
Table 1a.
Demographics of patients in RELESSER with juvenile onset systemic lupus erythematosus and of every cluster (n = 345)
Variable All patients Cluster 1 Cluster 2 Cluster 3 p value
n = 345 n = 251 (72.7%) n = 50 (14.6%) n = 44 (12.7%)
Gender, n (%) 0.121
Male 39 (11.3) 31 (12.4) 7 (14.0) 1 (2.3)
Female 306 (88.7) 220 (87.6) 43 (86.0) 43 (97.7)
Ethnicity, n (%) 0.478
0 Caucasian 313 (93.4)
1 Aphrican-American 1 (0.3)
2 Latin-American 15 (4.5)
3 Asian 2 (0.6)
4 Other 4 (1.2)
Caucasian 313 (90.7) 226 (92.6) 46 (93.9) 41 (97.6)
Non-Caucasian 22 (6.4) 18 (7.4) 3 (6.1) 1 (2.4)
Age at diagnosis (years), mean§ S.D. 14.25§ 2.89 14.34§ 2.97 13.65§ 3.06 14.45§ 2.17 0.250
Age at end of follow-up (years), mean§ S.D. 30.14§ 9.35 28.61§ 8.78 a,b 32.35§ 8.15 b,c 36.41§ 10.77 a,c <0.001
Follow-up time (months), mean§ S.D. 208.67§ 112.86 188.39§ 108.60 a,b 248.76§ 91.63 c 278.80§ 120.22 c <0.001
Abbreviations: Systemic Lupus International Collaboration Clinics American College of Rheumatology/Damage Index (SDI).
a Significantly different from cluster 2.
b Significantly different from cluster 3.
c Significantly different from cluster 1.
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of centre selection bias.Variables and definitions
Around 400 variables per patient were collected in the RELESSER
Registry [18]. For this study, the following variables were included in
the analyses:
 Demographic features: age, gender and ethnicity.
 Chronologic data: time of first symptom of the disease, time of
diagnosis of SLE, time of follow-up, date of every damage event
and date of death (if applicable).
 Cumulative manifestations of damage, using the definitions of the
SDI, at the time of the patient’s last medical visit (or death, if appli-
cable).Statistical analysis
Cluster analysis was carried out by applying k-means statistical
analysis (partitioning method) to identify those groups of SLE
patients with similar patterns of damage manifestation by the end of
the follow-up. The method starts with k clusters (fixed a priori) and
then moves patients among clusters with the goal of minimizing vari-
ability within clusters and maximizing variability between clusters.
Euclidean distance was used as a measure of similarity between the
damage profiles of two patients.
We ran the k-means analysis with 2, 3, 4 and 5 clusters and the
outputs were compared to each other. A plot of the total within-
groups sums of squares against the number of clusters was used to
choose the optimal number of clusters.
Three clusters of patients were finally compared. The comparison
of mortality among clusters was performed for the whole cohort and
for the subgroup of patients with disease duration < 5years. Results
were expressed as mean (SD) for continuous variables, and as number
of patients (percentages) for binary and categorical variables. The
ANOVA test was used to compare continuous variables. The chi-
squared test was employed to compare the frequencies of categorical
variables among the different clusters. Statistical significance was
concluded when P< 0.05.
All analyses were performed with R Statistical Software, version
3.1.1 (R Foundation for Statistical Computing, Vienna, Austria).Results
We collected data from 345 jSLE patients who fulfilled the inclu-
sion criteria. Baseline demographics, mortality data and specific dam-
age domain involvement from these jSLE patients are summarized in
Table 1a.
Cluster analysis
Among the 345 jSLE patients, three subgroups with similar dam-
age patterns were identified by k-means cluster analysis and then
compared. Cluster 1 included 251 (72.7%) patients, Cluster 2 50
(14.6%) patients and Cluster 3 44 (12.7%) patients. Characteristics
within the clusters and P-values for between-cluster comparisons are
shown in Table 1b.
Cluster 1 was the largest group, with mild overall damage or no
damage. Patients in this cluster had both lower mean SDI scores and
a lower mean number of domains involved compared to those in the
other two clusters.
Cluster 2 was the smallest group, with renal damage being pre-
dominant (60% of the patients). Ocular and cardiovascular damage
were present in 54% and 20% of the cases, respectively. Musculoskele-
tal damage was hardly present (2%). Patients in Cluster 2 had both the
highest mean SDI score and the highest mean number of domains
with damage.
All patients in Cluster 3 had musculoskeletal damage and it was
most frequently associated with peripheral vascular damage (15.9%).
However, renal damage was present only in 9.1% of cases. As was sim-
ilarly observed in Cluster 2, and in contrast to Cluster 1, all patients
showed at least one SDI domain involvement. There was no signifi-
cant difference in disease duration in Cluster 3 patients compared
with those in Cluster 2.
There were a total of 12 deaths. Patients in Cluster 2 had the high-
est mortality (10%), which was significantly higher than in Clusters 1
(2%) and 3 (4.5%), with P = 0.017 for all comparisons. In the group of
patients with disease duration < 5 years, there were only 3 deaths so
no meaningful conclusions can be drawn (Table 2).
Discussion
In a large national jSLE cohort we observed several clinical pat-
terns of damage manifestation and their association with different
risks of mortality. To the best of our knowledge, this is the first study
to perform such an analysis in jSLE. We found significant differences
among clusters not only in the proportion of patients with some kind
Table 1b.
Damage, damage distribution (per SDI domain) and mortality of patients in RELESSER with juvenile onset systemic lupus erythematosus and of every cluster (n = 345)
Variable All patients Cluster 1 Cluster 2 Cluster 3 p value
n = 345 n = 251 (72.7%) n = 50 (14.6%) n = 44 (12.7%)
SLICC ACR/DI Damage, n (%)
Ocular 32 (90.3) 0a,b 27 (54.0)b,c 5 (11.4)a,c <0.001
Neuropsychiatric 38 (11.0) 23 (9.2) 7 (14.0) 8 (18.2) 0.162
Renal 34 (9.9) 0a,b 30 (60.0)b,c 4 (9.1)a,c <0.001
Pulmonary 6 (1.7) 2 (0.8)b 1 (2.0) 3 (6.8)c 0.019
Cardiovascular 24 (7.0) 10 (4.0)a 10 (20.0)c 4 (9.1) <0.001
Peripheral vascular 24 (7.0) 12 (4.8)b 5 (10.0) 7 (15.9)c 0.018
Gastrointestinal 9 (2.6) 7 (2.8) 1 (2.0) 1 (2.3) 0.940
Musculoskeletal 45 (13.0) 0b 1 (2.0)b 44 (100)a,c <0.001
Cutaneous 9 (2.6) 3 (1.2)b 3 (6.0) 3 (6.8)c 0.026
Diabetes 2 (0.6) 2 (0.8) 0 0 0.686
Premature Gonadal Failure 17 (4.9) 7 (2.8)a 7 (14.0)c 3 (6.8) 0.003
Malignancy 8 (2.3) 6 (2.4) 1 (2.0) 1 (2.3) 0.986
SDI score, (mean§ S.D. 1.27§ 1.63 0.70§ 1.18 a,b 2.90§ 1.54c 2.66§ 1.87c <0.001
Any damage domain involved, n (%) 150 (43.5) 56 (22.3) 50 (100) 44 (100) <0.001
Number of domains involved, mean§ S.D. 0.72§ 1.02 0.29§ 0.59 a,b 1.86§ 0.93c 1.89§ 1.18c <0.001
Death, n (%) 12 (3.5) 5 (2.0) 5 (10.0) 2 (4.5) 0.017
Abbreviations: Systemic Lupus International Collaboration Clinics American College of Rheumatology/Damage Index (SDI).
a Significantly different from cluster 2.
b Significantly different from cluster 3.
c Significantly different from cluster 1.
Table 2.
Cluster analysis: damage involvement and mortality for those patients with disease
duration shorter than 5 years (n = 80)
Cluster 1 Cluster 2 Cluster 3 p-values
n = 72 (90.0%) n = 3 (3.8%) n = 5 (6.3%)
Age at diagnosis (years),
mean§ S.D.
14.22§ 3.07 13.97§ 3.53 14.26§ 2.77 0.949
Disease duration (months) 6.07 (15,95) 2.33 (1.94) 5.84 (4.22) 0.587
SDI score, mean§ S.D. 0.64§ 1.27 1.67§ 1.56b 2.60§ 2.07a 0.001
Patients with damage, n (%) 11 (15.3)a,b 3 (100)c 5 (100)c 0.005
Number of SDI domains
involved, mean§ S.D.
0.17§ 0.41a 1.33§ 0.58b,c 1.60§ 0.89a <0.001
Death, n (%) 2 (2.8) 0 (0) 1 (20.0) 0.295
Abbreviations: Systemic Lupus International Collaboration Clinics American College of
Rheumatology/Damage Index (SDI).
a Significantly different from cluster 2.
b Significantly different from cluster 3.
c Significantly different from cluster 1.
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ber of SDI domains affected and in the mean SDI score.
Similarly, as we previously observed in the global SLE population
[18], three distinct clusters based on damagemanifestations were identi-
fied, which we then explored for their association with mortality. Cluster
1 was the largest and the only one to include patients without damage.
All patients in Clusters 2 and 3 presented damage. However, these two
clusters differed significantly in terms of the predominant damage that
was present: patients with renal and cardiovascular damage mainly rep-
resented Cluster 2, while those with musculoskeletal damage comprised
almost all of Cluster 3. In an interesting recent publication, intense
immunosuppressant treatment and arthritis involvement were linked to
a higher number of flares per year and increased mortality. However, no
cluster was associated with renal involvement, probably due to the low
number of patients with this manifestation (13.6%) [19]. This observation
seems very unusual in a 366 cohort of SLE patients, and no information
about jSLE patients was mentioned. We previously found that jSLE
patients showed a higher prevalence of renal disease than aSLE, which
might easily lead to the presence of a specific cluster with a clear pre-
dominance of renal damage. The latter differed from what we observed
in aSLE patients, where a cluster with predominant cardiovascular dam-
age associated with higher mortality was found [18,20].
Predictors of damage in 473 jSLE patients followed into adulthood
(mean follow-up time 5.63years) have been recently assessed [21].
The authors found the following factors associated to damagethrough time: baseline life-threatening disease involvement, Afro-
Caribbean ethnicity, diagnosis within 1980s decade, each 10-mg
increment of prednisone, cyclophosphamide use and some of the
SLEDAI-2K items (psychosis, visual changes, lupus headache, pleurisy,
proteinuria, haematuria and fever). Antimalarial use protected
against increase of damage. In this study, a 2% of mortality rate was
found, approximately half of ours, but no associated factors were
evaluated,
In our study, mortality was higher in Cluster 2 compared to the
other clusters. This finding could be explained by the fact that cardio-
vascular involvement was more frequent in Cluster 2 (present in 20%
of cases) and also associated with renal damage (present in 60% of
cases). Renal damage has been described as a prognostic factor associ-
ated with higher mortality in SLE [17]. Based on our results, rheuma-
tologists and pediatric rheumatologists should be aware of the
presence of a specific subgroup of patients who mainly present renal
damage, but who may also present cardiovascular damage and high
mortality rates in jSLE. Whether this mortality might be prevented or
lowered is still unknown, but we believe better disease management
might prevent future renal failure, diminish renal damage, and proba-
bly mortality. It might also prove interesting to more carefully assess
cardiovascular disease in this specific patient subgroup. Based on pre-
vious research in aSLE, the LUMINA cohort and the RELESSER registry
revealed an association between mortality and renal and cardiovas-
cular damage, respectively [17,18]. These observations were con-
firmed in our study in jSLE as Cluster 2 combined renal and
cardiovascular damage and mortality. Since more jSLE patients suffer
from renal disease than adults and because it is also more severe at
onset and throughout disease evolution, such observations become
even more relevant for physicians who treat jSLE patients. In our pre-
vious study comparing aSLE and jSLE features, we pointed out not
only that renal disease more frequently flared in jSLE compared to
aSLE after its onset, but also that the histologic class changed in 25%
of re-biopsied kidneys. It is imperative to properly assess renal dis-
ease in SLE in order to be even more precise and aggressive, when
necessary, in treating jSLE patients [20].
The limitations of this study include its cross-sectional design,
since longitudinal studies can more adequately assess mortality over
time. The low number of deaths within the jSLE group could also
have limited our analyses. Another limitation is that the SDI index
was not specifically designed for assessing damage in jSLE (for
instance, the possibility of curing osteonecrosis in children, or the
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On the other hand, our study has several strengths: the rigorous man-
ner in which clinical data were collected to ensure comprehensive-
ness and the large number of patients derived from numerous
centres across the entire country with a long follow-up duration and
an appreciable number of deaths over time.
Conclusions
In conclusion, this is the first study to analyze and identify differ-
ent patterns (clusters) of damage manifestations within a large cohort
of jSLE patients. Renal and musculoskeletal damage were the two
dominant forms of damage used to sort these patients into clinically
meaningful clusters. Our study suggests that musculoskeletal, and
particularly renal damage, manifestations are significantly associated
with an increased risk of mortality. Therefore, physicians should pay
special attention to the early prevention of damage in this particular
subset of jSLE patients who present kidney involvement.
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